<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04193878</url>
  </required_header>
  <id_info>
    <org_study_id>53599</org_study_id>
    <secondary_id>1UG3HL141722-01A1</secondary_id>
    <nct_id>NCT04193878</nct_id>
  </id_info>
  <brief_title>ARrest RESpiraTory Failure From PNEUMONIA</brief_title>
  <acronym>ARREST</acronym>
  <official_title>ARrest RESpiraTory Failure From PNEUMONIA (ARREST PNEUMONIA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study seeks to establish the effectiveness of a combination of an inhaled
      corticosteroid and a beta agonist compared to placebo for the prevention of acute respiratory
      failure (ARF) in hospitalized patients with pneumonia and hypoxemia.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2020</start_date>
  <completion_date type="Anticipated">June 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acute respiratory failure (ARF)</measure>
    <time_frame>within 10 days of randomization</time_frame>
    <description>High flow nasal cannula (HFNC) and/or Noninvasive ventilation (NIV) use for greater than 36 hours OR Invasive mechanical ventilation for greater than 36 hours OR Death in a patient placed on respiratory support (HFNC, NIV, ventilator) who dies before 36 hours</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hospital length of stay</measure>
    <time_frame>within 60 days of randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of need for supplemental oxygen</measure>
    <time_frame>within 60 days of randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients intubated for respiratory failure</measure>
    <time_frame>Within 10 days of randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>World Health Organization (WHO) ordinal scale</measure>
    <time_frame>Within 10 days of randomization</time_frame>
    <description>The minimum value is death and the maximum is &quot;not hospitalized, no limitations on activities&quot;. Lower values are worse.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Pneumonia</condition>
  <condition>Hypoxemia</condition>
  <condition>Acute Respiratory Failure</condition>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>4 ml aerosolized 0.9% saline every 12 hours x 14 doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>aerosolized formoterol (20 mcg/2 ml) and budesonide (1.0 mg/2 ml) every 12 hours x 14 doses</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inhaled budesonide and formoterol</intervention_name>
    <description>aerosolized doses of budesonide (1.0 mg/2 ml) and formoterol (20 mg/2 ml) twice daily for up to 7 days</description>
    <arm_group_label>Intervention</arm_group_label>
    <other_name>Pulmicort Respules (budesonide) and Perforomist (formoterol)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inhaled placebo</intervention_name>
    <description>aerosolized saline (4 ml of 0.9% saline) twice daily for up to 7 days</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>aerosolized 0.9% saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Severe Pneumonia defined as hospitalization for acute (&lt; 7 days) onset of symptoms
             (cough, sputum production, or dyspnea) and radiographic evidence of pneumonia by chest
             radiograph or CT scan and evidence of systemic inflammation (temperature &lt; 35oC or &gt;
             38oC or WBC &lt; 4000 or &gt; 11,000 or procalcitonin &gt; 0.5 mcg/L),

        or

          -  Confirmed or high-clinical suspicion (defined by fever &gt; 100.4, and either cough or
             shortness of breath, and absence of alternative diagnosis) for COVID-19 infection

        and

          -  Hypoxemia defined as new requirement for supplemental oxygen with SpO2 &lt; 90% on room
             air, ≤ 96% on ≥ 2 L/min oxygen, or &gt; 6L/min or NIV (regardless of SpO2) at enrollment.

        Exclusion Criteria:

          -  Inability to obtain consent within 12 hours of meeting entry criteria

          -  Intubation (or impending intubation) prior to enrollment (This does not include those
             patients receiving High flow nasal cannula (HFNC) oxygen or Noninvasive ventilation
             (NIV) prior to enrollment)

          -  A condition requiring inhaled corticosteroids or beta-agonists, or chronic systemic
             steroid therapy equivalent to a dose &gt;10 mg prednisone (this does not include patients
             receiving inhaled beta-agonists in the Emergency Department without an established
             indication if treating clinician is willing to discontinue subsequent treatments)

          -  Do Not Intubate order but does not include a &quot;Do Not Resuscitate&quot; order

          -  Chronic lung or neuromuscular disease requiring daytime oxygen or mechanical
             ventilation other than for obstructive sleep apnea (OSA) or obesity hypoventilation
             syndrome

          -  Not anticipated to survive &gt; 48 hours or not expected to require &gt; 48 hours of
             hospitalization

          -  Contraindication or known allergy to inhaled corticosteroids or beta-agonists

          -  Patients with heart rate &gt; 130 bpm, ventricular tachycardia or new supraventricular
             tachycardia within last 4 hours will be potentially eligible for enrollment after the
             condition has resolved

          -  Patients with K+ &lt; 3.0 will be potentially eligible for enrollment after the condition
             has resolved

          -  Pregnancy

          -  Incarcerated individual

          -  Physician refusal of consent to protocol

          -  Patient/surrogate refusal of consent to protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joe Levitt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joe Levitt, MD</last_name>
    <phone>650-723-6381</phone>
    <email>jlevitt@stanford.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Emir Festic, MD</last_name>
    <email>Festic.Emir@mayo.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic - Scottsdale</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rodrigo Cartin-Ceba, MD</last_name>
      <email>cartinceba.rodrigo@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Rodrigo Cartin-Ceba, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Arizona</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Bime, MD</last_name>
      <email>cbime@deptofmed.arizona.edu</email>
    </contact>
    <investigator>
      <last_name>Christian Bime, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joe Levitt, MD</last_name>
      <phone>650-723-6381</phone>
      <email>jlevitt@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Joe Levitt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32608</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marie-Carmelle Elie, MD</last_name>
      <email>elie@ufl.edu</email>
    </contact>
    <investigator>
      <last_name>Marie-Carmelle Elie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic - Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emir Festic, MD</last_name>
      <email>Festic.Emir@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Emir Festic, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William Checkley, MD, PhD</last_name>
      <email>wcheckl1@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>William Checkley, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic - Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rahul Kashyap, MBBS</last_name>
      <email>Kashyap.Rahul@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Ognjen Gajic, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rahul Kashyap, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York University - Langone Health</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David Kaufman, MD</last_name>
      <email>David.A.Kaufman@nyumc.org</email>
    </contact>
    <investigator>
      <last_name>David Kaufman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ian Welsby, MD</last_name>
      <email>ian.welsby@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Ian Welsby, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Temple University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nina Gentile, MD</last_name>
      <email>ngentile@temple.edu</email>
    </contact>
    <investigator>
      <last_name>Nina Gentile, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>December 3, 2019</study_first_submitted>
  <study_first_submitted_qc>December 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 10, 2019</study_first_posted>
  <last_update_submitted>July 13, 2020</last_update_submitted>
  <last_update_submitted_qc>July 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Respiratory Insufficiency</mesh_term>
    <mesh_term>Hypoxia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Budesonide</mesh_term>
    <mesh_term>Formoterol Fumarate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

